In a report released today, Marc Frahm from Cowen & Co. maintained a Hold rating on Unum Therapeutics Inc (NASDAQ: UMRX). The company’s shares opened today at $11.99.
According to TipRanks.com, Frahm is a 2-star analyst with an average return of 0.8% and a 45.5% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Merrimack Pharmaceuticals, Adaptimmune Therapeutics, and Blueprint Medicines.
Currently, the analyst consensus on Unum Therapeutics Inc is a Moderate Buy with an average price target of $20.
See today’s analyst top recommended stocks >>
The company has a one-year high of $17.66 and a one-year low of $10.15. Currently, Unum Therapeutics Inc has an average volume of 392.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies.
